{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/XSTO/SE0007577895",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Vicore Pharma Holding AB (Nasdaq Stockholm: SE0007577895) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Vicore Pharma Holding AB, listed on Nasdaq Stockholm under ticker SE0007577895 with ISIN SE0007577895 and LEI 549300KTNBPTZLF01130. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 37 filings across 36 filing days in the twelve months to 2026-11-06. The median gap between filing days is 7 days. The latest filing is dated 2026-11-05 and is of type Interim report (Q1 and Q3), 1 day before the record date. Nasdaq Stockholm holds 398 issuers with a median of 30.0 filings, a median cadence gap of 9.5 days and a median latency of 7.0 days. The issuer's 37 filings are above that median, its cadence gap of 7 days is below it, and its latency of 1 day is below it. The sector median is not on the record.\n\n## Auditor\n\nThe auditor of record is not on the record, nor is its location. Auditor changes are not on the record, as the market's record does not carry them.\n\n## Events and halts\n\nThe record does not carry listing, delisting, name change, domicile change or segment move events, as no lifecycle type map exists for this register. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable because the chapter's orderability section carries no client categories. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names 11 research houses: ABG Sundal Collier, Cantor, Danske Bank, DNB Carnegie, Guggenheim, Jefferies, Pareto Securities, Stifel, Van Lanschot Kempen, Arctic Securities and Chardan.\n\n## Open research\n\nThe record holds 1 openly published research note, by goetzpartners securities Limited, dated 2018-03-22.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nNo issuer years are sealed. The market's vintage is not sealed, so no earliest sealed date is given and the live record's start is not on the record.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/XSTO/SE0007577895 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://vicorepharma.com/investerare/aktieinformation-2/analytiker/ (coverage)\n- http://vicorepharma.com/wp-content/uploads/2019/06/goetz-partners-vph-180322.pdf (open research)\n- https://mcp.se-cm-kg.ai/record/XSTO/SE0007577895 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/XSTO/SE0007577895",
  "coverage": {
   "count": 11,
   "houses": [
    {
     "analyst": "Georg Tigalonov-Bjerke",
     "house": "ABG Sundal Collier",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Steve Seedhouse",
     "house": "Cantor",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Gonzalo Artiach",
     "house": "Danske Bank",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Arvid Necander",
     "house": "DNB Carnegie",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Vamil Divan",
     "house": "Guggenheim",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Faisal Khurshid",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Chien-Hsun Lee",
     "house": "Pareto Securities",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Clemence Thiers",
     "house": "Stifel",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Sushila Hernandez",
     "house": "Van Lanschot Kempen",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "house": "Arctic Securities",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "house": "Chardan",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "result": "read: 11 of 20 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 398,
     "median_cadence_gap_days": 9.5,
     "median_filings": 30,
     "median_latency_days": 7,
     "name": "Nasdaq Stockholm"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual Financial Report": 1,
    "Decisions of general meeting": 1,
    "Financial Statement Release": 1,
    "Half Year financial report": 1,
    "Inside information": 3,
    "Interim report (Q1 and Q3)": 2,
    "Investor News": 24,
    "Notice to general meeting": 1,
    "Other information disclosed according to the rules of the Exchange": 1,
    "Total number of voting rights and capital": 2
   },
   "cadence_median_gap_days": 7,
   "filing_days": 36,
   "filings": 37,
   "latency_days": 1,
   "latest": [
    {
     "category": "Interim report (Q1 and Q3)",
     "date": "2026-11-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=b2a8c12f7031547f2a5139e3055b5665b&lang=en&src=listed",
     "title": "Vicore Pharma Announces Third Quarter 2026 Financial Results and Provides Business Update",
     "type": "Interim report (Q1 and Q3)"
    },
    {
     "category": "Other information disclosed according to the rules of the Exchange",
     "date": "2026-11-03",
     "source": "https://view.news.eu.nasdaq.com/view?id=befb0c3fa4ae5abc9b57fb8020f38227a&lang=en&src=listed",
     "title": "Vicore Announces the Nomination Committee for the 2027 Annual General Meeting",
     "type": "Other information disclosed according to the rules of the Exchange"
    },
    {
     "category": "Investor News",
     "date": "2026-11-02",
     "source": "https://view.news.eu.nasdaq.com/view?id=b4ef811734d14f1aa7f88e0c1ee197e3a&lang=en&src=listed",
     "title": "Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference",
     "type": "Investor News"
    },
    {
     "category": "Inside information",
     "date": "2026-10-22",
     "source": "https://view.news.eu.nasdaq.com/view?id=b062baa424bebb3835c71a77c9bd92203&lang=en&src=listed",
     "title": "Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results",
     "type": "Inside information"
    },
    {
     "category": "Investor News",
     "date": "2026-10-13",
     "source": "https://view.news.eu.nasdaq.com/view?id=bc8c529a9107a104457ba990531afbe70&lang=en&src=listed",
     "title": "Vicore Pharma to Participate in the Chardan Healthcare Conference",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0007577895",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Stockholm"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0007577895"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0007577895)",
    "state": "sourced",
    "value": "549300KTNBPTZLF01130"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Vicore Pharma Holding AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0007577895"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:f37a1601e30963bd7fe5e64a7660e63c717b69e2f5d4dcbed06cb55c2db395d9",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2018-03-22",
     "kind": "issuer-sponsored",
     "publisher": "goetzpartners securities Limited",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "http://vicorepharma.com/wp-content/uploads/2019/06/goetz-partners-vph-180322.pdf",
     "state": "sourced",
     "title": "Novel approach to tackle fibrotic orphan diseases"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/XSTO/SE0007577895",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:f37a1601e30963bd7fe5e64a7660e63c717b69e2f5d4dcbed06cb55c2db395d9",
 "path": "/se/XSTO/SE0007577895",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Vicore Pharma Holding AB, listed on Nasdaq Stockholm under ticker SE0007577895 with ISIN SE0007577895 and LEI 549300KTNBPTZLF01130. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 37 filings across 36 filing days in the twelve months to 2026-11-06. The median gap between filing days is 7 days. The latest filing is dated 2026-11-05 and is of type Interim report (Q1 and Q3), 1 day before the record date. Nasdaq Stockholm holds 398 issuers with a median of 30.0 filings, a median cadence gap of 9.5 days and a median latency of 7.0 days. The issuer's 37 filings are above that median, its cadence gap of 7 days is below it, and its latency of 1 day is below it. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, nor is its location. Auditor changes are not on the record, as the market's record does not carry them.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record does not carry listing, delisting, name change, domicile change or segment move events, as no lifecycle type map exists for this register. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable because the chapter's orderability section carries no client categories. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 11 research houses: ABG Sundal Collier, Cantor, Danske Bank, DNB Carnegie, Guggenheim, Jefferies, Pareto Securities, Stifel, Van Lanschot Kempen, Arctic Securities and Chardan.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 1 openly published research note, by goetzpartners securities Limited, dated 2018-03-22.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "No issuer years are sealed. The market's vintage is not sealed, so no earliest sealed date is given and the live record's start is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0007577895"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/"
  },
  {
   "for": "open research",
   "source": "http://vicorepharma.com/wp-content/uploads/2019/06/goetz-partners-vph-180322.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/XSTO/SE0007577895"
  }
 ],
 "title": "Vicore Pharma Holding AB (SE0007577895) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}